GLP-1 Obesity Drug Boom: U.S. and Korea-Listed Companies Redefining Healthcare and Markets
📘 Part 1. U.S.-Listed Leaders — The “Obesity Drug One-Tops” Already Making Real Money Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE ADR: NVO / Copenhagen: NOVO-B) are already generating substantial revenue and profit from GLP-1–based obesity and diabetes therapies. While many biotechs still trade on potential , these two have validated the business model. Contents Eli Lilly — Mounjaro & Zepbound Novo Nordisk — Ozempic & Wegovy U.S. Followers (Amgen, Viking) Part 2. Korea-Listed Names (Hanmi, HK inno.N, Ildong, D&D) Part 3. By the Numbers — Market & Tables Part 4. Final Framing — What to Use & What to Buy Sources When you talk about the obesity-treatment market of the 2020s, it ultimately boils down to two names: Eli Lilly and Novo Nordisk . Let’s go one by ...